November 28, 2014 2:00 AM ET

Pharmaceuticals

Company Overview of Cordex Pharma, Inc.

Company Overview

Cordex Pharma, Inc., through its subsidiary, Duska Scientific Co., develops cardiovascular medicines based upon the pharmacology of adenosine 5-triphosphate (ATP) and nitric oxide (NO). The company's product portfolio includes ATPace, which is used to treat paroxysmal supraventricular tachycardia; CDP-1050, a once-a-day tablet formulation to restore the redox-NO balance in patients with chronic heart failure; and Vagonixen, a drug to treat chronic obstructive pulmonary disease and chronic cough. Its products also comprise ATPotent, a drug for the treatment of sperm of infertile males in conjunction with in vitro fertilization and intra-uterine insemination procedure; and Ocuprene, a drug for...

470 Nautilus Street

Suite 300

La Jolla, CA 92037

United States

2 Employees

Phone:

858-551-5700

Fax:

858-551-5704

Key Executives for Cordex Pharma, Inc.

Medical Director of Duska Scientific Co
Age: 55
Compensation as of Fiscal Year 2014.

Cordex Pharma, Inc. Key Developments

SEC Orders Hearings On Registration Suspension Or Revocation Against Cordex Pharma, Inc. For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Cordex Pharma, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

Similar Private Companies By Industry

Company Name Region
Heart Rhythm Technologies Incorporated United States
Warner Chilcott Finance LLC United States
BPI Sports Holdings, LLC United States
Spring Bank Pharmaceuticals, Inc. United States
G2B Pharma, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cordex Pharma, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.